80 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Atp2b2m1Mae/Atp2b2+ Ppargtm2Mae/Pparg+ involves: 129S6/SvEvTac * C57BL/6J	abnormal prepulse inhibition	J:110607
	decreased startle reflex	J:110607
	impaired hearing	J:110607
Atp2b2m1Mae/Atp2b2m1Mae Ppargtm2Mae/Ppargtm2Mae involves: 129S6/SvEvTac * C57BL/6J	abnormal blinking	J:110607
	abnormal gait	J:110607
	abnormal motor coordination/balance	J:110607
	abnormal prepulse inhibition	J:110607
	abnormal reflex	J:110607
	abnormal vibrissae reflex	J:110607
	absent pinna reflex	J:110607
	absent startle reflex	J:110607
	ataxia	J:110607
	decreased body size	J:110607
	decreased grip strength	J:110607
	head bobbing	J:110607
	impaired balance	J:110607
	impaired hearing	J:110607
	impaired righting response	J:110607
	postnatal growth retardation	J:110607
	tremors	J:110607
Ctnnb1tm1Mmt/Ctnnb1+ Ppargtm1.1(tTA)Jmgr/Pparg+ Tg(tetO-cre)1Jaw/0 involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6	abnormal osteoclast differentiation	J:178340
	abnormal trabecular bone morphology	J:178340
	absent bone marrow cell	J:178340
	decreased bone marrow cell number	J:178340
	decreased bone resorption	J:178340
	decreased osteoclast cell number	J:178340
	extramedullary hematopoiesis	J:178340
	increased bone trabecula number	J:178340
	increased bone volume	J:178340
	increased compact bone volume	J:178340
	increased splenocyte number	J:178340
	increased trabecular bone thickness	J:178340
	increased trabecular bone volume	J:178340
	osteopetrosis	J:178340
	normal skeleton phenotype	J:178340
Ctnnb1tm2Kem/Ctnnb1+ Ppargtm1.1(tTA)Jmgr/Pparg+ Tg(tetO-cre)1Jaw/0 involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal osteoclast physiology	J:178340
	abnormal trabecular bone morphology	J:178340
	decreased bone trabecula number	J:178340
	decreased trabecular bone mass	J:178340
	decreased trabecular bone thickness	J:178340
	decreased trabecular bone volume	J:178340
	increased bone resorption	J:178340
	increased osteoclast cell number	J:178340
	osteoporosis	J:178340
	normal skeleton phenotype	J:178340
Ctnnb1tm2Kem/Ctnnb1tm2Kem Ppargtm1.1(tTA)Jmgr/Pparg+ Tg(tetO-cre)1Jaw/0 involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal osteoclast physiology	J:178340
	abnormal trabecular bone morphology	J:178340
	decreased bone resorption	J:178340
	decreased osteoclast cell number	J:178340
	extramedullary hematopoiesis	J:178340
	increased bone trabecula number	J:178340
	increased bone volume	J:178340
	increased compact bone volume	J:178340
	increased trabecular bone thickness	J:178340
	increased trabecular bone volume	J:178340
	osteopetrosis	J:178340
	normal skeleton phenotype	J:178340
Ctnnb1tm2Kem/Ctnnb1tm2Kem Ppargtm1.1(tTA)Jmgr/Pparg+ Tg(tetO-cre)1Jaw/0 Tg(tetO-HIST1H2BJ/GFP)47Efu/0 involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1	abnormal osteoclast differentiation	J:178340
Dok1tm1Yyam/Dok1tm1Yyam Ppargtm1Laz/Ppargtm1Laz involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6	abnormal fat cell morphology	J:133566
	normal adipose tissue phenotype	J:133566
Lepob/Lepob Ppargtm1Avp/Pparg+ involves: 129S2/SvPas * C57BL/6	abnormal glucose homeostasis	J:116568
	abnormal gonadal fat pad morphology	J:116568
	abnormal skeletal muscle morphology	J:116568
	abnormal white adipose tissue amount	J:116568
	decreased body fat mass	J:116568
	decreased body weight	J:116568
	decreased circulating adiponectin level	J:116568
	decreased fat cell size	J:116568
	hepatic steatosis	J:116568
	increased circulating glucose level	J:116568
	increased circulating insulin level	J:116568
	increased circulating triglyceride level	J:116568
	increased liver weight	J:116568
	insulin resistance	J:116568
	polyphagia	J:116568
Lepob/Lepob Ppargtm2Avp/Ppargtm2Avp involves: 129 * C57BL/6	abnormal fat cell morphology	J:121534
	abnormal glucose homeostasis	J:121534
	abnormal insulin secretion	J:121534
	abnormal lipid homeostasis	J:121534
	abnormal liver morphology	J:121534
	abnormal locomotor behavior	J:121534
	abnormal pancreatic islet morphology	J:121534
	abnormal skeletal muscle morphology	J:121534
	decreased circulating adiponectin level	J:121534
	decreased circulating insulin level	J:121534
	decreased liver triglyceride level	J:121534
	decreased locomotor activity	J:121534
	decreased respiratory quotient	J:121534
	decreased triglyceride level	J:121534
	disorganized pancreatic islets	J:121534
	normal endocrine/exocrine gland phenotype	J:121534
	normal growth/size/body region phenotype	J:121534
	hepatic steatosis	J:121534
	hyperglycemia	J:121534
	increased circulating free fatty acids level	J:121534
	increased circulating glucose level	J:121534
	increased circulating insulin level	J:121534
	increased circulating triglyceride level	J:121534
	increased fluid intake	J:121534
	increased percent body fat/body weight	J:121534
	increased urine glucose level	J:121534
	insulin resistance	J:121534
	oxidative stress	J:121534
	polyphagia	J:121534
Ppargtm1.1Unc/Pparg+ involves: 129S6/SvEvTac * C57BL/6J	decreased systemic arterial blood pressure	J:154767
Ppargtm1.1Unc/Ppargtm1.1Unc involves: 129S6/SvEvTac * C57BL/6J	decreased systemic arterial blood pressure	J:154767
	normal homeostasis/metabolism phenotype	J:154767
	impaired glucose tolerance	J:154767